C-peptide replacement improves weight gain and renal function in diabetic rats

Area of Science:

• Endocrinology
• Nephrology
• Metabolic Research

Background:

• Type 1 diabetes is associated with diabetic nephropathy, a leading cause of kidney failure.
• C-peptide replacement therapy is being investigated for its potential benefits in managing diabetes complications.

Purpose of the Study:

• To evaluate the effects of physiological C-peptide administration on metabolic status and renal function in type 1 diabetic rats.
• To determine if C-peptide replacement therapy can mitigate diabetic nephropathy.

Main Methods:

• Four groups of rats were used: non-diabetic control, diabetic control, diabetic treated with insulin, and diabetic treated with C-peptide.
• Animals were monitored for weight gain, metabolic parameters, and renal function markers including proteinuria and glomerular filtration rate (GFR).
• Blood and urine samples were analyzed for osmolality, C-peptide, sodium, and glucose levels.

Main Results:

• C-peptide administration improved weight gain in diabetic rats, irrespective of glycemic control.
• Diabetic rats treated with C-peptide showed significantly reduced glomerular hyperfiltration, proteinuria, and urinary sodium loss compared to untreated diabetic rats.
• While insulin improved glycemic control, C-peptide treatment demonstrated comparable benefits in weight gain and superior renal protection.

Conclusions:

• C-peptide replacement therapy in a type 1 diabetes rat model promotes weight gain and enhances renal function.
• C-peptide supplementation effectively reduces key markers of diabetic nephropathy, including hyperfiltration, proteinuria, and sodium wasting.
• These findings suggest C-peptide replacement therapy holds promise for managing diabetic nephropathy in type 1 diabetes.